Abstract
Background: Transforming growth factor-β (TGF-β) is a multifunctional cytokine that has been linked to vascular remodeling processes, myocardial hypertrophy, and renal fibrosis. The aim of the present study was to evaluate the clinical value of tgfβ1as a tumor marker for the diagnosis and postoperative follow- up of patients suffering from RCC.
Methods: A total of 36 patients were included in the study. These patients were first evaluated for RCC and then later confirmed by HPE. tgfβ1 in plasma samples was estimated by using a commercially available ELISA kit From DRG INTERNATIONAL, Inc GmbH Germany.
Results: After HPE clear cell type was the most common type (25/32 -78.1%), followed by papillary type (4/32 -15.6%), chromophobic type (2/32 -6.2%) and angiomyolipoma (1/32 -3.1%). Out of 36 patients 29 (80.5%) patients had no lymph nodes and 7 (19.4%) patients were positive for lymph nodes. 36 Patients of RCC showed elevated level of tgfβ1as compared to the control group. Comparing these tgfβ1 levels with the localized RCC group having mean levels 25527.42 ng/l, a statistically significant difference (P<0.05) was found.
Conclusions: The present study indicates that tgfβ1 levels in RCC patients irrespective of pathological stage of tumor & or metastasis remain quite high even after nephrectomy & even upto six months of follow up. Thus tgfβ1 levels alone cannot be used as single prognostic marker to monitor the progression of disease or treatment in RCC.
Keywords: Transforming growth factor-β1 - diagnosis - monitoring – prognosis, renal cell carcinoma (RCC).
References
- Lawrence DA (1995) Transforming growth factor-β: an overview. Kidney Int 49:S19–23.
- Roberts AB, Sporn MB (1990):The transforming growth factor-β. In: Sporn MB, Roberts AB (eds) Peptide growth factors and their receptors. Handbook of experimental pharmacology. Heidelberg: Springer Verlag, pp 419–472
- Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factorβ type 1 binds to collagen IV of basement membrane matrix: implications for development. DevelBiol 1991;143:303–8.
- Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990;346:281–4.
- Webb DJ, Crookston KP, Figler NL, LaMarre J, Gonias SL. Differences in the binding of transforming growth factor β 1 to the acute-phase reactant and constitutively synthesized alpha-macroglobulins of rat. Biochem J 1995;312:579–86.
- Webb DJ, Crookston KP, Hall SW, Gonias SL. Binding of transforming growth factor-β1 to immobilized human alpha2-macroglobulin. Arch BiochemBiophys 1992;292:487–92.
- Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155–62.
- Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995;89:45–8.
- Muller F, Aukrust P, Nilssen DE, Froland SS. Reduced serum level of transforming growth factor-β in patients with IgA deficiency. Clin Immunol Immunopathol 1995;76:203–8.
- Jiang X, Kanai H, Hiromura K, Sawamura M, Yano S. Increased intraplatelet and urinary transforming growth factor-β in patients with multiple myeloma. Acta Haematol 1995;94:1–6.
- Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MIV, Brenchley PEC. Plasma TGF β in systemic sclerosis: a crosssectional study. Ann Rheum Dis 1994;53:763.
- Hegele A et al (2002): TGF-β1 in patients with renal cell carcinoma Urol Res (2002) 30: 126–129
- Kugler A (1999) Matrix metalloproteinases and their inhibitors. Anticancer Res 19(2C):1589–1592.
- Nicol D, Hii SI, WalshM, TehB, Thompson L, Kennett C, Gotley D (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157:1482–1486.
- Wechsel HW, Feil G, Oremek GM, Bichler KH, Gleichmann.R (2001) The inactive form of pyruvate kinase in tumor diagnosis:an overview of the current state of research. AktUrol 32:55–61.
- Amanda Ewart-Toland, June M. Chan, Jinwei Yuan, Allan Balmain, and Jing Ma:A Gain of Function TGFΒ1 Polymorphism May Be associated With Late Stage Prostate Cancer Cancer Epidemiol Biomarkers Prev 2004;13(5). May 2004.
- Bellam N, Pasche B. Cancer Tgf-β signaling alterations and colon cance Treat Res. 2010; 155:85-103.
- Ken Yamazaki, YoheiMasugi, Michiie Sakamoto Molecular Pathogenesis of Hepatocellular Carcinoma: Altering Transforming Growth Factor-β Signaling in Hepatocarcinogenesis Dig Dis2011;29:284-288 (DOI: 10.1159/000327560).
- Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155–62.
- Junker U ,et al (1996):Transforming growthfactor β 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 8:794–798.
- Wunderlich H, et al (1998) Increased transforming growth factor b1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? UrolInt 60:205–207
- Kropf J, Schurek JO, Wollner A, Gressner AM (1997) Immunological measurement of transforming growthfactor-β1 (TGF-β1) in blood; assay development and comparison. Clin Chem 43:1965–1974.
Corresponding Author
Naveed Khan
Consultant, Kidney Hospital Srinagar India
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile No: +91-9650976696
DOI: https://dx.doi.org/10.18535/jmscr/v7i3.216
